Keywords: trigen, completes, ph, study, oral, anti-coagulant, tgn
Trigen completes Ph I study with oral anti-coagulant TGN 167
Article | 22 December 2003
UK biotechnology firm Trigen says it has successfully completed aPhase I dose-escalation study of its highly-selective oral direct thrombin inhibitor ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
